Open AccessIL‐2 gene C/T polymorphism is associated with prostate cancer
Author(s) -
Wu HsiChin,
Chang ChaoHsiang,
Wan Lei,
Wu ChaoI,
Tsai FuuJen,
Chen WenChi
Publication year - 2006
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.20149
Subject(s) - prostate cancer , genotype , gene polymorphism , oncology , medicine , gene , cancer , prostate , biology , genetics
Abstract Cytokines are reported to be associated with the formation of prostate cancer. Our aim was to investigate whether C/T polymorphisms of the interleukin‐2 (IL‐2) gene and IL‐2 receptor beta (IL‐2RB) gene are associated with prostate cancer. We compared the frequency of the polymorphisms of the IL‐2 gene and the IL‐2RB gene between 96 patients with prostate cancer and 105 healthy male volunteers from the same area (age >60 years). They were followed for at least 5 years. There was a significant difference in distribution of the genotype of the IL‐2 gene polymorphism between the prostate cancer group and the control group ( P = 0.017). The distribution of the TT homozygote of the IL‐2 gene was significantly higher in the cancer group (32.3%) than in the control group (16.2%). However, no significant statistical difference was found between the polymorphism of the IL‐2 gene and prostate cancer in survival analysis during a 5‐year follow up period (log rank test; P = 0.19). There was no significant difference in the distribution of the genotype of the IL‐2RB gene polymorphism between controls and cancer patients ( P = 0.388). This study suggests that the IL‐2 gene may be associated with susceptibility to prostate cancer in the Taiwan population. J. Clin. Lab. Anal. 20:245–249, 2006. © 2006 Wiley‐Liss, Inc.